Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience
- 5 July 2016
- journal article
- research article
- Published by Springer Nature in Endocrine Pathology
- Vol. 27 (4) , 359-362
Abstract
Medullary thyroid carcinoma (MTC) harbors rearranged during transfection (RET) gene and rarely RAS gene mutations. The knowledge of the type of gene mutation in MTC is important to determine the treatment of the patients and the management of their family members. Targeted next-generation sequencing with a panel of 47 genes was performed in a total of 12 cases of sporadic (9/12) and hereditary MTC (3/12). Two of three hereditary MTCs had RET/C634R mutation, while the other one harbored two RET mutations (L790F and S649L). All the sporadic MTC had RET/M918T mutation except one case with HRAS mutation. Next-generation sequencing (NGS) can provide comprehensive analysis of molecular alterations in MTC in a routine clinical setting, which facilitate the management of the patient and the family members.Keywords
This publication has 30 references indexed in Scilit:
- Using “residual” FNA rinse and body fluid specimens for next‐generation sequencing: An institutional experienceCancer Cytopathology, 2015
- The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromesExperimental and Molecular Pathology, 2015
- RET revisited: expanding the oncogenic portfolioNature Reviews Cancer, 2014
- Targeted next‐generation sequencing using fine‐needle aspirates from adenocarcinomas of the lungCancer Cytopathology, 2013
- SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonThe Journal of Clinical Endocrinology & Metabolism, 2012
- Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsiesVirchows Archiv, 2012
- The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine TumorsPancreas, 2010
- Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791*Clinical Endocrinology, 2008
- Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.European Journal of Endocrinology, 2008
- A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995Cancer, 1998